http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2320300-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0de3c2a3b6a654048399cc756869a0f3
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
filingDate 2006-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7df85aa00961757ecd2664bac3b02cd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efc34f67d1b925eb84695db9e9b4d44b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4352a1e714bcee5a9e1c4dfd44dccf45
publicationDate 2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2320300-C1
titleOfInvention Complex therapy method for treating optical neuritis cases
abstract FIELD: medicine. n SUBSTANCE: method involves delivering drugs directly to optic nerve via infusion system placed in retrobulbar space. 4 mg of Dexamethason in 1 ml of solution is introduced beginning from 8 o'clock in the morning every 30 min. The first three days, it takes place 5 times at daily dose of 20 mg. Daily dose of 16 mg is given four times at the fourth and fifth day. Daily dose of 12 mg is administered three times at the sixth and seventh day. Daily dose of 8 mg is given twice at the eighth and ninth day. Daily dose of 4 mg is given once at the tenth day. Trental, Emoxipin, Solcoseryl and Taufon are delivered to the optic nerve afternoons at a dose of 0.5 ml each, beginning from 12 o'clock with 2 h long pause via infusion system. n EFFECT: accelerated treatment course; reduced risk of traumatic complications. n 1 tbl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2494709-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2623870-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2498826-C1
priorityDate 2006-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4740
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419479655
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407866699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506968
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1712095
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419474858
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533859
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3100
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533897
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489743
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492800
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497675
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1123
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41375
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1986

Total number of triples: 41.